Challenges of defining reliable clinical surrogate end points in haemophilia trials: A critical review

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 7, 2009, Pages 488-493

  Amby, Lene Klixbüll ^a   Seremetis, Stephanie ^a   Obergfell, Achim ^b   Bjerre, Jens ^a  

^a NOVO NORDISK A S   (Denmark)

^b Novo Nordisk FemCare AG   (Switzerland)

Author keywords

Algorithms; End points; Haemophilia; Validation

Indexed keywords

ANALGESIC AGENT; HEMOSTATIC AGENT; PLACEBO; BIOLOGICAL MARKER;

BLEEDING; CHILD CARE; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GERIATRIC CARE; HEMARTHROSIS; HEMOPHILIA; HEMOSTASIS; HUMAN; MEDICAL RESEARCH; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; CLINICAL TRIAL (TOPIC); HEMOPHILIA A; OUTCOME ASSESSMENT; PROCEDURES; STANDARDS;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; HEMOPHILIA A; HUMANS; METHODS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 70349804869     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832c8803     Document Type: Review

References (36)

1. World Federation of Haemophilia. Available at: http://www.wfh.org/ index.asp?lang=EN (Accessed 3 March 2009).
2. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004; 77:187-193.
3. Fischer K, van der Bom JG, Molho P, Negrier C, Mauser-Bunschoten EP, Roosendaal G, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8:745-752. (Pubitemid 35446626)
4. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244:515-522.
5. Steen Carlsson K, Höjgård S, Glomstein A, Lethagen S, Schulman S, Tengborn L, et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9:555-566.
6. Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients: a long-term follow-up. J Intern Med 1997; 241:395-400.
7. Petrini P, Lindvall N, Egberg N, Blombäck M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991; 13:280-287.
8. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357:535-544.
9. Panicker J, Warrier I, Thomas R, Lusher JM. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003; 9:272-278.
10. Committee for medical products for Human Use (CHMP). Guideline on the clinical investigation of recombinant factor VIII and IX products. European Medicines Agency (EMEA) Draft Guideline. CPMP/BPWG/1561/99 rev. 1. London, 19 July 2007. Available at: http://www.emea.europa.eu/pdfs/ human/bpwg/ 156199endraft.pdf (Accessed 3 March 2009).
11. DKFZ. Guideline on clinical trials in small populations (CHMP/EWP/ 83561/2005, Draft, 17 March, 2005). Available at: http://www.dkfzheidelberg. de/biostatistics/IBS/dokumente/Comments-CHMPEWP83561- DRIBS.pdf (Accessed 3 March 2009).
12. Medeiros D, Laufenberg JA, Miller KL, Buchanan GR. Short-term oral corticosteroid therapy for acute haemarthrosis in haemophilia patients with high-titre inhibitors. Haemophilia 2007; 13:85-89.
13. Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14:287-294.
14. Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G, NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multicentre, randomised, double-blind, cross-over trial. Thromb Haemost 2006; 95:600-605.
15. Shapiro AD. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors. Clin Adv Hematol Oncol 2008; 6:579-586.
16. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 7:517-522.
17. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scoraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4:367-371.
18. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006; 12:514-517.
19. Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall J, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14:466-475.
20. Arranz P, Remor E, Quintana M, Villar A, Dýaz JL, Moreno M, et al. Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia. Haemophilia 2004; 10:376-382. (Pubitemid 39089035)
21. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J Thromb Haemost 2003; 1:423-424.
22. Key NS, Aledort LM, Beardlsey D, Cooper HA, Davignon G, Ewenstein BM, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80:912-918.
23. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5:1904-1913.
24. Né grier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A, et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/ albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost 2008; 100:217-223.
25. Morfini M, Haya S, Tagariello G, Pollman H, Quintana M, Siegmund B, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13:606-612.
26. Scalone L, Mantovani LG, Mannucci PM, Gringeri A, The COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12:154-162.
27. Wasserman J, Aday LA, Begley CE, Ahn C, Lairson DR. Measuring health state p for hemophilia: development of a disease-specific utility instrument. Haemophilia 2005; 11:49-57.
28. Donfield SM, Astermark J, Lail AE, Gilbert SA, Berntorp E, Fenoc Study Group. Value added: increasing the power to assess treatment outcome in joint haemorrhages. Haemophilia 2008; 14:276-280.
29. Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr Med Res Opin 2006; 22:23-31.
30. Schobess R, Kurnik K, Friedrichs F, Halimeh S, Krümpel A, Bidlingmaier C, et al. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter nonconcurrent cohort study. Thromb Haemost 2008; 99:71-76.
31. Santagostino E, Morfini M, Rocino A, Baudo F, Scoraggi FA, Gringeri A. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VII inhibitors. Thromb Haemost 2001; 86:954-958.
32. Parameswaran R, Shapiro AD, Gill JC, Kessler CM, HTRS Registry Investigators. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11:100-106.
33. Abshire TC, Brackmann HH, Scharrer I, Hoots K, Gazengel C, Powell JS, et al. Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy: International Kogenate-FS Study Group. Thromb Haemost 2000; 83:811-816.
34. Seremetis S, Lusher JM, Abildgaard CF, Kasper CK, Allred R, Hurst D. Human recombinant DNA-derived antihaemophilic factor (factor VIII) in the treatment of haemophilia A: conclusions of a 5-year study of home therapy. The KOGENATE Study Group. Haemophilia 1999; 5:9-16.
35. Bray GL,Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood 1994; 83:2428-2435.
36. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9:464-520. (Pubitemid 36874393)